Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance

References

• Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011;8(4):244-50
   PubMed Web of Science ®Google Scholar
• DeVita VTJr, Lewis BJ, Rozencweig M, Muggia FM. The chemotherapy of Hodgkin’s disease: past experiences and future directions. Cancer 1978;42(2 Suppl):979-90
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253-65
   PubMed Web of Science ®Google Scholar
• Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012;18(1):51-63
   PubMed Web of Science ®Google Scholar
• Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis 2012;3:e411
   PubMed Web of Science ®Google Scholar
• Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012;23(1):1-6
   PubMed Web of Science ®Google Scholar
• Ni Chonghaile T, Sarosiek KA, Vo TT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011;334(6059):1129-33
   PubMed Web of Science ®Google Scholar
• Placzek WJ, Wei J, Kitada S, et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010;1:e40
   PubMed Web of Science ®Google Scholar
• Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7(12):989-1000
   PubMed Web of Science ®Google Scholar
• Wong M, Tan N, Zha J, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther 2012;11(4):1026-35
   PubMed Web of Science ®Google Scholar
• Colak S, Zimberlin CD, Fessler E, et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ 2014;21(7):1170-7
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15(1):49-63
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435(7042):677-81
   PubMed Web of Science ®Google Scholar
• Tan N, Malek M, Zha J, et al. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 2011;17(6):1394-404
   PubMed Web of Science ®Google Scholar
• Stamelos VA, Robinson E, Redman CW, Richardson A. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. Gynecol Oncol 2013;128(2):377-82
   PubMed Web of Science ®Google Scholar
• Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 2011;10(12):2340-9
   PubMed Web of Science ®Google Scholar
• Shortt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol 2012;4:12
   PubMed Web of Science ®Google Scholar
• Collard TJ, Urban BC, Patsos HA, et al. The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells. Cell Death Dis 2012;3:e408
   PubMed Web of Science ®Google Scholar
• Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11(11):761-74
   PubMed Web of Science ®Google Scholar
• Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000;14(19):2393-409
   PubMed Web of Science ®Google Scholar
• Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013;8:277-302
   PubMed Web of Science ®Google Scholar
• Barreca A, Martinengo C, Annaratone L, et al. Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. Blood Cancer J 2014;4:e249
   PubMed Web of Science ®Google Scholar
• Masir N, Campbell LJ, Goff LK, et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol 2009;144(5):716-25
   PubMed Web of Science ®Google Scholar
• Xia ZJ, Hu W, Wang YB, et al. Expression heterogeneity research of ITGB3 and BCL-2 in lung adenocarcinoma tissue and adenocarcinoma cell line. Asian Pac J Trop Med 2014;7(6):473-7
   PubMed Web of Science ®Google Scholar
• Ashton-Key M, Biddolph SC, Stein H, et al. Heterogeneity of bcl-2 expression in MALT lymphoma. Histopathology 1995;26(1):75-8
   PubMed Web of Science ®Google Scholar
• Schmid J, Dussmann H, Boukes GJ, et al. Systems analysis of cancer cell heterogeneity in caspase-dependent apoptosis subsequent to mitochondrial outer membrane permeabilization. J Biol Chem 2012;287(49):41546-59
   PubMed Web of Science ®Google Scholar
• Zhao B, Hemann MT, Lauffenburger DA. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci USA 2014;111(29):10773-8
   PubMed Web of Science ®Google Scholar
• Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013;105(7):452-8
   PubMedGoogle Scholar
• McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013;12(3):217-28
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7
   PubMed Web of Science ®Google Scholar
• Janssen A, Beerling E, Medema R, van Rheenen J. Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy. PLoS One 2013;8(5):e64029
   PubMed Web of Science ®Google Scholar
• Orth JD, Kohler RH, Foijer F, et al. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res 2011;71(13):4608-16
   PubMed Web of Science ®Google Scholar
• Tibbitt MW, Anseth KS. Dynamic microenvironments: the fourth dimension. Sci Transl Med 2012;4(160): 160ps124
   PubMed Web of Science ®Google Scholar